AONN+ Conference Abstracts

Navigation tactics include community needs assessments and education on early signs of cancer, screening guidelines, and community and state resources to support patient populations.

Navigation includes multidisciplinary, health system orientation as well as patient-centered education and empowerment to deliver timely and seamless care.

Navigators use research and outcomes to develop and validate navigation programs and services.

Navigation supports effective interprofessional collaboration, increased patient satisfaction, higher quality of care, and efficient use of healthcare resources.

Navigators are in a unique position to assess patient distress, which can range from sadness and fear to disabling problems such as depression, anxiety, and spiritual crisis.

Advocacy in navigation ensures integration of patient preferences into care delivery.

Identification of barriers to care and effective interventions to improve care processes.

Promotion of health, wellness, and care coordination throughout a patient’s life.

Innovative clinical and translational research evaluating novel therapies, pharmacology, and molecular alterations or biomarkers that predict treatment response, side effects, or resistance.

Impactful and ground-breaking, the late-breaking abstracts feature the latest, critically important research developments and highlight novel findings from practice-changing studies.

To examine how SEs impacting QOL in pts with ABC are perceived.

To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.

MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 10⁹/L.

Here, we present the primary analysis of the mBCC cohort.

Here, we present the long-term follow-up data at up to 40 months.

To assess OS at an updated cutoff with additional follow-up.

MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.^1,2

To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.

Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.

Prostate cancer is the most common male malignancy. In 2021, the United States will see an estimated 248,530 new cases, 34,130 deaths, and more than 3 million survivors.

The oncology nurse navigator (ONN) plays a central role in decreasing distress and increasing satisfaction in patients with breast cancer.

When a patient with prostate cancer needs radiation therapy (RT), their physician submits an order for RT to a prior authorization program, which assesses its concordance with clinical guidelines and evidence-based practices.